SweDeliver
Research forum in drug delivery, focusing on new strategies for parenteral, oral and pulmonary drug delivery.
News
- Do your degree project at SweDeliver's industrial partners 2022-01-04
- Pharmetheus increases SweDeliver commitment with new project 2022-01-03
- Center Director Christel Bergström After a very productive 2022 SweDeliver continues to grow 2021-12-17
- Apply now for a summer work in a research intensive environment 2021-12-17
- Self-learning machines will show the way to better drug therapies 2021-12-16
Seminars & Events
Online Symposium
27 january, 08:45–17:00
Pharmaceutical Profiling in Drug Discovery and Development
Degree project 2022
Student • Apply now
Experience research at the forefront of drug delivery
meet phd Student
Irès van der Zwaan
“The diversity that characterizes SweDeliver is inspiring to be part of”
Summer internship 22
"A win-win for all parties"
Conduct research at one of our 16 industrial partners
This is SweDeliver
SweDeliver is a world leading research and competence centre in Drug Delivery. Many novel molecules in the drug discovery and development pipeline are biological compounds such as proteins, peptides and RNA. These display problems of poor solubility, membrane permeability and low bioavailability. Thus, the Drug Delivery area is today facing tremendous challenges to develop new drug therapies.
SweDeliver was established in response to these challenges. Based on a multi-disciplinary collaboration between academia and industry with financial support from Vinnova (Sweden’s Innovation Agency), the Faculty of Pharmacy at Uppsala University is the academic hub of the Centre with 16 industrial partners contributing expertise and research infrastructure as well as industrial perspectives and needs within the three main research areas of the Centre.
SweDeliver has prioritized to focus on outstanding research challenges within
- Parenteral Drug Delivery
- Oral Drug Delivery
- Pulmonary Drug Delivery
The research will ultimately lead to development of new and improved drug therapies with respect to both efficacy and patient safety. The Centre will also further support the strong research environment and the drug delivery ecosystem in the Nordic region.
